Clinical Trials Browser

Phase 1 × TIC10 compound × Plasma cell × Clear all

NCT02609230 2021-06-04

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Phase 1 Completed

Multiple Myeloma